Tango Therapeutics, Inc. (TNGX)
| Market Cap | 4.76B +1,784.3% |
| Revenue (ttm) | 56.99M +39.0% |
| Net Income | -107.23M |
| EPS | -0.86 |
| Shares Out | 144.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,225,244 |
| Open | 31.33 |
| Previous Close | 30.94 |
| Day's Range | 30.75 - 33.00 |
| 52-Week Range | 4.40 - 33.00 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 40.45 (+22.95%) |
| Earnings Date | Aug 4, 2026 |
About TNGX
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to ... [Read more]
Financial Performance
In 2025, Tango Therapeutics's revenue was $62.38 million, an increase of 48.29% compared to the previous year's $42.07 million. Losses were -$101.59 million, -22.03% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for TNGX stock is "Strong Buy." The 12-month stock price target is $40.45, which is an increase of 22.95% from the latest price.
News
Tango Therapeutics 18.2M share Secondary priced at $30.00
The deal size was increased to $600M in common stock from $500M in common stock. JPMorgan, Leerink, Cantor Fitzgerald and Stifel acted as joint book running managers for the offering.
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of preci...
Tango Therapeutics price target raised to $66 from $27 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Tango Therapeutics (TNGX) to $66 from $27 and keeps a Buy rating on the shares after the company announced initial Phase 1…
Tango Therapeutics price target raised to $42 from $30 at Canaccord
Canaccord raised the firm’s price target on Tango Therapeutics (TNGX) to $42 from $30 and keeps a Buy rating on the shares. The firm updated its model following results that…
Tango Therapeutics announces $500M common stock offering
Tango Therapeutics (TNGX) announced the launch of an underwritten public offering of $500M of its common stock. All shares of common stock to be sold in the offering will be…
Tango Therapeutics Announces Proposed $500 Million Public Offering
BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of preci...
Tango Therapeutics stock soars on promising pancreatic cancer data
Shares of Tango Therapeutics (TNGX) surged more than 51% on Monday after the clinical-stage biotechnology company reported encouraging early-stage trial results for its experimental cancer treatment, ...
Tango Therapeutics price target raised to $69 from $55 at Leerink
Leerink raised the firm’s price target on Tango Therapeutics (TNGX) to $69 from $55 and keeps an Outperform rating on the shares after the company provided details from its ongoing…
Tango Therapeutics price target raised to $36 from $30 at Mizuho
Mizuho analyst Joseph Catanzaro raised the firm’s price target on Tango Therapeutics (TNGX) to $36 from $30 and keeps an Outperform rating on the shares following this morning’s topline disclosure…
Tango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer Treatment
Tango Therapeutics stock soars after the biotech company announces initial data from its ongoing study on pancreatic cancer. An analyst calls the results ‘unprecedented.
Tango Therapeutics rises 45.5%
Tango Therapeutics (TNGX) is up 45.5%, or $9.19 to $29.41.
Tango Therapeutics upgraded at Wolfe after ‘impressive’ vopimetsotat combo data
Wolfe Research analyst Kalpit Patel upgraded Tango Therapeutics (TNGX) to Outperform from Peer Perform with a $35 price target after the vopimetsotat plus daraxonrasib combination “impressively” showe...
Tango Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research upgraded Tango Therapeutics (TNGX) to Outperform from Peer Perform with a $35 price target
Tango Therapeutics price target raised to $35 from $21 at B. Riley
B. Riley raised the firm’s price target on Tango Therapeutics (TNGX) to $35 from $21 and keeps a Buy rating on the shares after the company reported an “unprecedented” 92%…
Tango Therapeutics rises 32.1%
Tango Therapeutics (TNGX) is up 32.1%, or $6.50 to $26.72.
RBC Capital says Tango-Revolution data strengthens daraxonrasib’s PDAC position
RBC Capital notes that Tango Therapeutics (TNGX) announced data from the combo of their PRMT5 inhibitor vopimetostat and Revolution Medicines’ (RVMD) Marax or zoldon. The firm thinks the data supports...
Tango Therapeutics' pancreatic cancer drug combo shows promise in study
Tango Therapeutics said on Monday an experimental drug combination showed strong early results in a small study of patients with advanced pancreatic cancer and that it plans to advance the treatment ...
Tango Therapeutics Transcript: Study result
Combination of vopimetostat with pan-RAS inhibitors in MTAP-deleted pancreatic cancer showed a 92% response rate and 90% six-month PFS, with strong durability and tolerability. Plans include a phase III trial in first-line patients and expansion into other cancers.
Tango Therapeutics Press release: Study result
Tango Therapeutics issued a press release on June 8, 2026, disclosing material business information to investors.
Tango Therapeutics Slides: Study result
Tango Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
Tango Therapeutics announces data from study of vopimetostat, daraxonrasib
Tango Therapeutics (TNGX) announced positive initial data from its ongoing Phase 1/2 study of vopimetostat, an investigational PRMT5 inhibitor with first- and best-in-class potential, in combination w...
Tango Therapeutics Slides: Investor presentation
Tango Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting ...
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective June 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors gr...
Tango Therapeutics Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation approval. All proposals passed, with directors elected through 2029 and PricewaterhouseCoopers confirmed as auditor. Forward-looking risks were noted.